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Abstract 
Postoperative acute kidney injury (AKI) is a frequent perioperative complication that 
negatively affects morbidity and mortality. Mannitol is frequently used perioperatively for 
renal protection, although evidence for its use is ambiguous. We conducted a systematic 
review to clarify whether there is evidence supporting perioperative mannitol 
administration for the prevention of postoperative AKI.  
A systematic literature search was performed in Medline/ Pubmed, Embase, the 
Cochrane Library, Clinical Trials registry, and the Cochrane Central Register of 
Controlled Trials (CENTRAL). Eligibility criteria were (1) population: studies involving 
adult patients undergoing surgery or a related intervention; (2) intervention: i.v. mannitol 
administered in either the pre-operative or intra-operative period with comparison to 
control subjects; and (3) predefined outcomes: postoperative AKI or respective renal 
endpoints/surrogates. 
We identified 1,538 articles published between January 1990 and  October 2018. After 
checking for eligibility, 22 studies including 17 prospective and/or randomized controlled 
trials and 5 retrospective studies were included. The investigations involved various 
fields of surgery, such as aortic surgery, cardiac surgery with cardiopulmonary bypass, 
and urological procedures including partial nephrectomy. Significant heterogeneity, 
limited sample size, and mostly short follow-up periods were noted. 
Given available evidence, the perioperative use of mannitol to prevent  AKI cannot be 
considered an evidence-based intervention in cardiac surgery, partial nephrectomy, 
and/or other major surgery. Further research is required with a focus on patients at high 
risk for postoperative AKI. 
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What this paper adds: 
Postoperative acute kidney injury is known as an independent risk factor for both short- 
and long-term mortality. The diuretic mannitol is often used in cardiovascular surgery 
and  other surgical fields for renal protection. This systematic review substantiates that 
perioperative use of mannitol for AKI prevention should not be considered an evidence-
based intervention in cardiac and vascular surgery, partial nephrectomy, and/or other 
major surgery. This seems because data mostly derive from heterogeneous cohorts with 
limited samples size. Further research seems required with a focus on high risk patients 
for postoperative AKI.  
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Introduction 
Postoperative acute kidney injury (AKI) is a frequent complication and an independent 
risk factor for both short- and long-term morbidity and mortality. (1-4) The incidence of 
postoperative AKI is 20-37%(5) in open aortic repair, 20-30% in procedures performed 
with the use of cardiopulmonary bypass(6, 7) and 1% up to 32% in non-cardiac major 
surgery.(2-4)  In 2-4% of vascular and cardiac surgery patients, renal replacement 
therapy (RRT) is needed(5). For cardiac surgery, AKI-related mortality of 4.5% is 
reported.(6) Although there is an urgent medical need for strategies to prevent 
perioperative AKI, most evaluated strategies have failed.(8-10) In some institutions, 
mannitol is used for perioperative renal protection in open aortic repair(11), in 
cardiopulmonary bypass procedures(12), in partial nephrectomy and in renal 
transplantation.(13) 
Mannitol is a sugar alcohol used as an osmotic diuretic. The substance is freely filtered 
and does not undergo tubular reabsorption. It increases intratubular osmotic pressure, 
thus enhancing free water excretion.(14) Mannitol has been reported to induce renal 
vasodilatation by decreasing renal vascular resistance (RVR) and thereby increasing 
renal blood flow (RBF) (14, 15), however, results are inconclusive. (16) Data deriving 
from experiments in both humans and animals show that in general, mannitol does not 
affect glomerular filtration rates (GFR).(14-16) In hypoperfused kidneys, some evidence 
deriving from research in animals shows that mannitol may increase or restore GFR(14), 
an effect that may partly be explained by a reduction in tubular cell swelling(14, 17), and 
prostaglandin-mediated vasodilatation.(18) Intratubular hydrostatic pressures are 
elevated after mannitol infusion in hypoxic kidneys, which may theoretically prevent 
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swelling and obstruction of renal tubules.(14, 17) In a recent study, Damasceno-Ferreira 
et al. demonstrated in a pig model that mannitol could prevent glomerular loss during 
warm ischemia. (19) Clinical parameters including urea and creatinine concentrations 
did not change significantly. (19) Moreover, mannitol was proposed to act as an oxygen 
free radical scavenger attenuating ischaemia–reperfusion injury. (20-22) Haraldsson et. 
al. and Khoury et al. could observe an effect of mannitol on direct and indirect renal 
ischemia-reperfusion injury in animals (20, 22). Some thus speculate that mannitol may 
have “renal protective” effects. On the other hand, case reports and retrospective data 
report AKI and osmotic nephrosis related to mannitol in patients with stroke, 
intracerebral hemorrhage, or trauma, who received high dose mannitol to treat increased 
intracranial pressure. (23-26) Mannitol-induced renal injury was related to renal tubular 
vacuolization and swelling of tubular cells(25, 27), in a dose-dependent fashion. Other 
risk factors for mannitol associated renal injury are concomitant use of diuretics, 
diabetes, higher initial National Institutes of Health Stroke Scale (NIHSS) scores, and/or 
renal insufficiency at admission.(26)  In most cases, mannitol-induced renal injury 
appears reversible after discontinuation. (25, 26)  
Although evidence remains ambiguous, mannitol is frequently administered in the 
perioperative setting in an effort to prevent renal injury. We therefore conducted a 
systematic review to clarify whether there is evidence in favor of administering 
perioperative mannitol prophylactically for postoperative AKI.  
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Methods    
This review was registered in the PROSPERO database (CRD42018099086), the 
international prospective register of systematic reviews. This article adheres to the 
applicable PRISMA guidelines on reporting items for Systematic Reviews and Meta-
Analyses.(28) 
Studies examining a potential influence of perioperative mannitol administration on 
postoperative renal function and published between January 1st, 1990 and  October 
2018, and were eligible for inclusion. Medline/Pubmed, Embase, the Cochrane Library, 
the Clinical Trials registry, and the Cochrane Central Register of Controlled Trials 
(CENTRAL) were searched using the terms “kidney”, “renal”, “perioperative” and 
“mannitol”  either alone or in combination (JW, CAP). Further, we searched the 
reference lists of all initially identified reports to identify additional potential publications 
(JW, CAP).  
Inclusion and exclusion criteria 
According to the PRISMA checklist for transparent reporting of systematic reviews, 
publications were included in the final analysis if all of the following criteria were met: (1) 
population: studies involving adult patients undergoing surgery or a related intervention; 
(2) intervention: i.v. mannitol administered in either the pre-operative or intra-operative 
period with comparison to control subjects; (3) predefined outcomes: postoperative AKI 
or respective renal endpoints/surrogates. Studies with endpoints other than renal 
function (i.e.trials on mannitol in renal replacement therapy, on prevention of intracranial 
or intraocular pressure, or investigations on orally administered or inhaled mannitol) or 
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surrogates of renal function, and reports not written in English or German were 
excluded. 
Data collection process 
All potentially eligible papers were assessed in detail. Data extraction (JW) was 
performed using a predesigned form and checked by a second reviewer (CAP). The 
following data were extracted: first author, publication year, type of surgery or 
intervention, study intervention and control group, sample size, incomplete reporting, 
allocation and randomization, blinding, primary and secondary outcomes, follow-up 
period. 
Bias 
An attempt was made to minimize bias with a comprehensive search strategy including 
non-published data. Methodological quality and the risk of bias within the reviewed 
RCTs were assessed according to the Cochrane Handbook for Systematic Reviews of 
Interventions. (29) For this purpose, six items were evaluated for each study included: (I) 
random sequence generation and (II) allocation concealment (selection bias), (III) 
blinding of participants and personnel (performance bias), (IV) blinding of outcome 
assessment (detection bias), (V) incomplete outcome data (attrition bias) and (VI) 
selective reporting (reporting bias). The Assessment was performed independently by 
three authors (JW, ASM and CP). 
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Results 
 1,538 records were identified in the primary search after removal of duplicates (Fig. 1). 
After screening for eligibility,  1,505 publications were excluded based on the predefined 
inclusion and exclusion criteria. Thirty-three publications were evaluated in detail. After 
exclusion of another 11 records (full text not available in English or German, conference 
abstract with no full text published, mannitol applied postoperatively, no control group) 
(Fig. 1),  22 reports remained in the final analysis (17 prospective and/or randomized 
controlled trials [RCTs] and five retrospective studies).  
Out of 22 reports in the final analysis, three RCTs and one retrospective study reported 
use of mannitol in elective open or endovascular repair of the abdominal aorta. The use 
of mannitol in elective cardiac surgery was studied in seven trials. The application of 
mannitol in extracorporeal shock wave lithotripsy (ESWL) was examined in two RCTs 
and in living donor kidney transplantation in one RCT. Two RCT and  three retrospective 
studies evaluated the use of mannitol in partial nephrectomy. One RCT studied mannitol 
in liver transplantation and one in surgery for obstructive jaundice. One retrospective 
study evaluated mannitol in robot-assisted laparoscopic radical prostatectomy (RALP).  
The quality of RCTs included in our systematic review was assessed by the Cochrane 
Collaboration tool (29) (Table 3). Almost two thirds of the included RCTs are of unclear 
risk of bias (10/16).  Six studies are of low risk for bias and one of high risk. Most often, 
uncertainty of bias was related to (I) random sequence generation, (II) allocation 
concealment (selection bias), (IV) blinding of outcome assessment (detection bias) and 
(V) incomplete outcome data (attrition bias) (Table 3, Figure 2).  Most RCTs provided no 
power analysis and were of small size (median n=42, range 118-199). In total they 
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included 904 patients. Follow-up periods in the RCTs chosen were short (range 12h 
postoperatively until six months), whereas the sample size of the included retrospective 
studies(30-32) varied from n=55 to n=476 (median n=285), with a total of 1,569 patients. 
The follow-up period was up to 13 months. Further information is provided in Table 1 
and 2. 
Mannitol in vascular surgery 
Three RCTs studied the effect of mannitol on AKI in vascular surgery.(33-35)  Two of 
these were performed in patients with open aortic repair and infrarenal clamping and 
one in endovascular aortic repair (EVAR). 
Nicholson et al. included 28 patients and compared 0.3g/kg mannitol as a rapid i.v. bolus 
before cross-clamping of the aorta against placebo.(35) Patients in the mannitol arm had 
lower levels of urinary albumin/creatinine ratio (160±32 vs. 500±140 mg/mmol; p=.04) 
and urinary N-acetyl-β-D-glucosaminidase (NAG)/creatinine ratio (143±34 vs. 271±70 
pmol/mmol; p=.04) at 24 hours postoperatively. Differences in day 7 creatinine 
clearance and postoperative complications or mortality were not observed.(35) 
Wijnen et al. compared a co-intervention with different anti-oxidative substances, 
including a mannitol infusion over 12 hours, with the authors’ standard care. The authors 
reported an increased creatinine clearance on day 2 in patients receiving the 
intervention when compared to controls (106±90 vs. 73±76 ml/min/1,73m2, p=.047), but 
this effect was not preserved through day 7.(34) In EVAR, 86 patients were treated with 
a mannitol bolus and hydration or with hydration alone.(33) When compared to controls, 
patients in the intervention arm had lower 24h serum creatinine (1.07±0.26 vs. 
1.20±0.30mg/dl, p<.05). Serum-cystatin-C levels were lower in the mannitol group at 24 
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hours (2.2±0.8 vs. controls 2.6±0.9mg/l, p<.05) but not at 72 hours. No differences in 
AKI according to the RIFLE classification and no differences in urinary neutrophil 
gelatinase-associated lipocalin (NGAL) levels were observed.(33) 
A retrospective study in 169 patients undergoing aortic repair with suprarenal clamping 
but without cold renal perfusion identified mannitol (0.5 g/kg, range 0.1-1.0 g/kg) as 
renoprotective (odds ratio [OR] 0.3; 95% confidence interval [CI] 0.1-0.8) for AKI 
development according to the RIFLE (Risk, Injury, Failure, Loss of kidney function, and 
endstage renal disease) classification.(30)  
Mannitol in cardiac surgery 
Several smaller studies were performed in cardiac surgery patients. 
Fisher et al. compared different doses of mannitol vs. placebo. The group studied 
urinary output as a surrogate for renal function and showed an increase in urinary output 
in the mannitol group.(36)  
A smaller study by Ip-Yam et al. compared mannitol 0.5 g/kg added to the 
cardiopulmonary bypass (CPB) prime in a normothermic group vs. a hypothermic regime 
and a standard-of-care regime. No differences were observed in creatinine clearance, 
fractional sodium excretion, microalbuminuria, or urinary NAG.(37) 
Three other studies compared mannitol as an additive to the cardiopulmonary bypass 
(CBP) prime or as an infusion vs. mannitol plus dopamine infusion vs. dopamine alone 
or placebo.(38-40) Significant differences were not identified in any of the chosen 
surrogates of AKI, except for one study that found a significant increase in β2-
microglobulin (β2M) in the dopamine groups (dopamine alone vs. placebo and 
    11 
 
 
dopamine + mannitol vs. placebo: 2.48±3.61μg/min vs. 0.59±1.04 μg/min; p=.001 and 
2.05±2.77μg/min vs 0.59±1.04 μg/min; p=.007) at one hour post-CBP.(40) 
Yallop et al. and Smith et al. conducted high-quality studies in cardiac surgery patients 
with either normal creatinine baseline levels or established renal dysfunction (41, 42). 
Both studies revealed no differences in chosen surrogates of renal function within the 
first postoperative days.  
Mannitol in renal surgery 
Five RCTs and  four retrospective studies investigated mannitol in urology. Muter et al. 
used the Doppler-based renal resistive index (RI) to evaluate potential renoprotective 
effects of mannitol in patients receiving ESWL.(43) A slightly lower RI was observed in 
patients receiving mannitol before ESWL when compared to controls.(43) Nevertheless, 
the clinical significance of this finding remains unclear. 
Ogiste et al. used urinary β2-microglobulin(β2M)-to-creatinine ratio and the 
microalbumin-to-creatinine  ratio as surrogates of kidney injury and found a significant 
increase in the urinary β2M-to-creatinine ratio directly after ESWL, but not on day 1 or 
7.(44) 
In renal transplantation, an RCT by Esfahani et al. evaluated mannitol versus no 
intervention in living donor kidney transplantation. No difference in the chosen endpoints 
(urine volume, serum urea and creatinine) under investigation were observed.(45)  
A recent RCT by Spaliviero et al. studied potential effects of mannitol in nephron-sparing 
surgery (NSS) in 199 patients with preoperative estimated GFR (eGFR) >45 
ml/min/1.73m2. (46) The authors identified no significant differences in eGFR at 6 weeks 
or 6 months as well as in renal radionuclear scintigraphy scans at 6 months. In 65 
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patients who underwent robotic-assisted-laparoscopic partial nephrectomy (RALPN), 
Choi K et al. observed no difference between individuals receiving 12g mannitol vs. 
controls.(47) 
Four retrospective studies showed no benefits of mannitol use in partial nephrectomy or 
RALPN. (31, 32, 48, 49) 
In respective studies and the trial by Spaliviero et al., kidney hypothermia was at least 
partly used as an additional renoprotective measure, primarily in controls.(31, 32, 46) 
 
Mannitol in liver surgery 
Wahbah et al. evaluated different combinations of dopamine and mannitol vs. controls in 
obstructive jaundice.(50) No differences in any of the chosen endpoints were noted.(50) 
One study tested mannitol as a reno-protective agent in orthotopic liver transplantation, 
but the authors did not observe any between-group differences with regard to fluid 
balance, urinary output, or 24h creatinine clearance in a short-follow-up period .(51) 
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Discussion 
Despite conflicting data (10), mannitol is still applied in clinical practice for prevention of 
postoperative AKI.(11-13) In the current systematic review, we analyzed data from 16 
RCTs and 3 retrospective studies examining the effects of perioperative mannitol use in 
a broad spectrum of surgical fields. To date this is the largest review examining the 
effect of perioperative application of mannitol on AKI, with the broadest spectrum of 
surgical procedures. 
In one retrospective study in open abdominal aortic surgery with suprarenal clamping, 
mannitol was identified as a potential renoprotective factor.(30) RCTs in vascular 
surgery and in ESWL observed effects related to early biomarkers of tubular cell 
damage.(33-35, 44) None of the RCTs observed any differences in AKI or patient-
centered clinical outcome measures, such as postoperative complications or mortality. 
Two retrospective studies in partial nephrectomy revealed no benefits for mannitol 
either. This is supported by a meta-analysis by Yang et al. including only five 
perioperative trials and 215 patients,(52) which found no benefits for i.v. mannitol in 
terms of AKI prevention. No evidence was found in another review on mannitol in open 
abdominal aortic aneurysm surgery covering mostly older studies.(53)  
When interpreting available data on the perioperative use of mannitol to prevent 
postoperative AKI, it is important to note that both potential (i.e., theoretical) benefits as 
well as mostly negative trial data for mannitol exist. There may be several reasons for 
this. 
First, although AKI is a frequent postoperative complication with typical incidences 
ranging from 20-37% in high-risk surgery, most of the included RCTs appear to be 
    14 
 
 
underpowered (Table 1), with only  904 patients from RCTs summarized in this review. 
Therefore, there is still a demand for larger, adequately powered studies to examine the 
pharmacological agents available for AKI prevention.(10) 
Second, perioperative renal injury may result from multiple etiologies. Patient co-
morbidities(54), pre-renal fluid status(8), inflammation(55), direct ischemia(30), ischemic 
embolism (56), influence of toxins or oxidative mechanisms (57) (58) and cardiac 
function (9) may all affect AKI development. Thus, mannitol could theoretically provide 
benefits for some but not all etiologies. Nevertheless, in combination with optimal goal-
directed fluid therapy, mannitol may optimize RBF and renal function.(15) Yet without 
concomitant fluid therapy or in combination with other diuretics, mannitol may even 
worsen renal function, as seen for example in patients treated with mannitol for high 
intracranial pressure.(26)  
Third, careful patient selection may be key for a strategy to prevent AKI. In procedures 
with a higher risk of postoperative renal injury, such as aortic surgery and suprarenal 
clamping, mannitol may be protective. Furthermore, alternative methods for renal 
protection, such as cold kidney perfusion, may abolish potential protective effects of 
mannitol, even with similar or prolonged clamping times. This may at least partially 
explain the contradictory results of the retrospective studies.(30-32) 
Fourth, measurement of glomerular filtration rates could be regarded as gold standard 
for assessment of renal function. Given that this is unpractical for perioperative use, 
most investigations used serum creatinine or urine output to assess renal function. Thus, 
the authors adhere to the Kidney Disease Improving Global Outcome (KDIGO) Clinical 
Practice Guidelines that define changes in serum creatinine levels and/or (de-creased) 
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urinary volumes as the most relevant indices in AKI .(59)  Nevertheless, changes in 
creatinine and/or decrease in urinary output are regarded as late (functional) markers of 
renal dysfunction. (60) and diagnosis of AKI based on creatinine (or urine output) may 
thus underestimate renal damage, especially in short observational periods in non-
steady state conditions.(10, 60) 
In an effort to detect AKI early, several new biomarkers were proposed in the last 
years.(61)  Some were tested in studies included in this review (e.g. NGAL, Cystatin C 
and others). (33, 35, 37-39)  Among these, Cystatin C and NGAL might be most 
promising. Cystatin C, a 13-kDa protein is freely filtered, reabsorbed, and metabolized in 
the proximal tubule.(62, 63) Serum, Cystatin C levels correlate well with GFR and 
increased urinary Cystatin C excretion reflects AKI as its uptake is reduce by damaged 
tubules. (62, 63) With a Cystatin C half-life of about one third of the half-life of creatinine, 
steady state conditions may be reached faster.(64)  NGAL is a 25-kDa protein from 
human neutrophils. (62)  Increased NGAL concentrations in urine and plasma were 
shown to reflect AKI and predict adverse clinical outcomes (e.g. need for RRT, 
mortality). (62, 63)   
Nevertheless, although new biomarkers appear promising, it appears that further 
research is required before they could be applied in daily clinical use.  The matrix of 
testing, AKI-related specificity, and potential confounding medications could influence 
cutoffs and diagnostic value. (62-64)  
Limitations to this analysis include the fact that we deliberately restricted our literature 
research to studies performed after 1990 assuming that surgical technique, 
anesthesiological management and study design has evolved in the last 30 years.  
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Furthermore, studies included appear heterogeneous with regard to different mannitol 
regimes applied, different endpoints, and different sample sizes. Due to this 
heterogeneity, performing of a meta-analysis did not seem reasonable. 
Moreover, we found a retrospective study (Reese J. et al., The Journal of Urology. 
2017;197(4S): e1273) of mannitol in partial nephrectomy which was published as 
abstracts only and  was therefore not included . Nevertheless, the respective study 
showed no benefit of mannitol.  
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Conclusions 
Despite theoretical benefits, current evidence does not support the use of mannitol as a 
renal protective perioperative measure in cardiopulmonary bypass procedures, partial 
nephrectomy, or other major types of surgery. Some evidence hints at a potential benefit 
in abdominal aortic surgery, especially in patients with suprarenal clamping. Further 
adequately powered studies are required to determine whether there is a place for 
mannitol in the perioperative setting in specific indications. 
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Surgery 
Intervention Control Sample 
size 
Blinding, 
Random- 
ization 
Outcome, 
Follow-Up 
Nicholson 
et al. 1996 
(28) 
 
Elective 
aortic 
repair, 
infra-renal 
clamp 
Mannitol 
0.3g/kg i.v. 
before cross-
clamping 
Normal 
saline 
n=28, 
(1:1) 
Unblinded. 
Randomized 
(sealed 
envelope). 
Urine output, CrCl, BUN, 
sCr, urinary albumin and 
uNAG. LOS in ICU.  
Until 7th day 
Wijnen  et 
al. 2001 
(42) 
 
Elective 
open infra-
renal aortic 
repair 
Antioxidants: 
vitamine E, 
vitamine C, allo-
purinol, N-
acetylcysteine, 
mannitol 0.5g/ 
12h  
Standard-of 
care-therapy  
n=42 
(1:1) 
Unblinded. 
Randomized 
(method not 
mentioned). 
CrCl, microalbumin in 
urine. 
Until 7th day post-surgery 
Kalimeris 
et al. 2014 
(27)  
 
 
Endo-
vascular 
aortic repair 
(EVAR) 
Mannitol 
0.5g/kg i.v. + 
hydration 
(500ml Ringer's 
lactate + 
2ml/kg/h + 
losses) 
Hydration  n=86 
(1:1) 
Unblinded. 
Randomized 
(sealed 
envelope). 
Primary Outcome:  
sCR,  AKI (RIFLE 
criteria), 
secondary outcomes: 
Serum-Cystatin-C, 
urinary NGAL at 24 + 72h  
Narin et al. 
2015 (36) 
 
Elective  
CABG-
surgery 
Group I : 
mannitol 1g/kg 
in CPB-prime.                                             
II:DA 2 
μg/kg/min i.v.  
III: DA + 
mannitol.  
IV: furo-
semide i.v. 
(low urinary
output) 
n=100, 
(1:1) 
Unblinded. 
Unclear or no 
randomi-
zation. 
Urinary microalbumin, 
urinary creatinine and 
serum cystatin-c values. 
Until 2nd day 
Yallop et 
al. 2008 
(29) 
 
Elective 
cardiac 
surgery in 
patients 
with normal 
baseline 
creatinine  
5 ml/kg mannitol 
in CPB-prime 
Ringer's 
lactate 
added to 
CBP-prime 
n=40  
(1:1) 
Blinded 
(except 
perfusionist). 
Randomized 
(Computer-
generated 
random 
number) 
Retinol binding protein 
(RBP), microalbumin; 
sCr;  blood urea nitrogen 
(BUN); urine-output, fluid 
balance. 
Until 5th day 
Smith et 
al. 2008 
(30) 
 
Elective  
CABG in 
patients 
with 
established 
renal 
dysfunction 
0.5g/kg 
mannitol  (CPB-
prime)  
Ringer's 
lactate 
(CBP-prime) 
n= 47 
(1:1) 
Blinded 
(except 
perfusionist). 
Randomized 
(random 
number) 
Daily urine output, fluid 
intake, plasma creatinine, 
urea. 
Until 3rd day. 
Carcoana  
et al. 2003 
(35) 
 
 
Elective, 
primary 
CABG 
requiring 
CPB. 
Group 2: 
mannitol 1 g/kg  
(CBP-prime) + 
placebo-
infusion,                                                    
group 3: DA 
2µg/kg/min + 
placebo (CBP-
prime)                                        
group 4: DA + 
mannitol  
Group 1): 
normal 
saline as 
infusion and 
added to
CBP-prime 
n=100                            
(1:1:1:1) 
Double-
blinded. 
Randomized 
(random-
number 
tables) 
Primary outcome: 
β2M 1h post-CBP; 
secondary outcome: β2M 
at 6 + 24h, CrCl, sCr, 
urinary flow rates, 
LenghOS-ICU, 
hospitalization, clinical 
events. 
Until hospital discharge 
Dural et al. 
1999(31) 
Elective 
coronary 
artery 
surgery 
Group I : DA 
3µg/kg/min i.v.      
Group II: 
mannitol 1 
mg/kg/h i.v.  
Group III: 
standard-of-
care 
n=36 , 
(1:1:1) 
 
Unblinded. 
Randomized 
(method not 
mentioned). 
NAG activity, levels of 
serum, urinary creatinine, 
and BUN. 
Until 2nd day 
Fisher et 
al. 
1998(43) 
Elective 
CABG 
surgery 
Group 2: 10 g  
mannitol (CBP-
prime)                                           
3: 20g mannitol 
added 
4: 30g mannitol 
added 
Group 1:  no 
mannitol 
added 
n=76 
(1:1:1:1) 
Unblinded. 
Randomized 
(method not 
mentioned). 
Urine output. 
12h  after surgery 
 Surgery Intervention Control Sample 
size 
Blinding, 
Random- 
ization 
Outcome, 
Follow-Up 
Ip-Yam et 
al. 
1994(44) 
Elective 
CABG 
surgery 
Group H: 
moderate 
hypothermia 
(28°C)                   
Group M: 37°C  
+ mannitol 
0.5g/kg (CPB 
prime) 
Group N: 
37°C + no 
mannitol 
n=24                                                     
(1:1:1) 
 
Unblinded.
Randomized 
(method not 
mentioned). 
sCr, sNa, urinary NAG 
and microalbumin, CrCl,  
FEN. 
Until 6th day 
Esfahani 
et al. 2014 
(32) 
Living 
Donor 
Kidney 
Trans-
plantation 
Mannitol, dose 
not mentioned 
No Mannitol n=60, 
(1:1) 
Blinded data-
collection. 
Randomized 
(alternating 
numbers). 
Urine-volume (first 24h), 
BUN, sCr. 
Until hospital discharge 
Muter et 
al. 
2009(37) 
ESWL 0.5g/kg 
mannitol 
immediately 
before ESWL 
Non n=38                                       
(1:1) 
 
Unblinded.
Randomized 
(method not 
mentioned). 
Renal resistive index. 
Until day 7   
Ogiste et 
al. 
2003(45) 
ESWL 0.5 g/kg 
mannitol i.v. 
immediately 
before ESWL 
Non n=18,  
(1:1) 
Unblinded. 
Randomized 
(method not 
mentioned). 
β2M and microalbumin. 
7th day after procedure 
 
Spaliviero 
et al. 2017 
(33) 
 
Nephron 
sparing 
surgery in 
renal mass 
Mannitol 12.5g 
i.v. within 30 
min prior renal 
vascular 
clamping 
Normal 
saline 
n=199 
(1:1) 
Double-
blinded. 
Randomized 
(permuted 
blocks) 
sCR and eGFR, split 
function on 6-mo renal 
scan, grade 3–5 
complications within 30 d 
of surgery. 
Choi et al 
2018 
RALPN  12 g mannitol in 
50 ml normal 
saline 
50 ml normal 
saline 
n=79  
n=65 
analysed 
(1.1:1) 
Double-
blinded. 
Computer-
generated 
randomized 
schedule 
Primary outcome: GFR at 
24 h,1 week, and 30 days                                                  
Secondary outcome: 
percent change in eGFR 
at 24 h, 1 week, and 30 
days, complications and 
readmissions 
Whitta et 
al. 
2001(34) 
Orthotopic 
liver trans-
plantation  
0.5 g/kg 
mannitol i.v.  
Normal 
saline 
n=25 
(1:1) 
Double-
blinding. 
Randomized 
(random 
number) 
24hours-creatinine- 
clearance, fluid intakes, 
urine output. 
24h postoperative. 
Wahbah et 
al. 
2000(38) 
Surgery in 
obstructive 
jaundice 
Group II:  DA 
2.5μg/kg/min i.v.                
III: DA + 
mannitol 
0.25mg/kg i.v.  
 IV: DA 
+furosemide 
1mg/kg i.v.  
Group I: 
controls, fluid 
therapy only 
n=40,  
(1:1:1:1) 
Unblinded. 
Randomized 
(method not 
mentioned). 
24h-urine-output, sCr, 
creatinine-clearance. 
Until day 7. 
Table  1 
 
 
 
 
 
 
 
 Surgery Intervention Control Sample 
size 
Blinding, 
Random- 
ization 
Outcome, 
Follow-Up 
Dubois et al. 
2013(39) 
Elective 
juxta-renal 
aortic repair  
Retro-
spective 
study 
Mannitol  0.5 
g/kg (range, 
0.1-1.0 g/kg) 
i.v. 
 
No mannitol. 
 
n=169 
(3:1) 
 
n.a. Postoperative 
renal 
dysfunction 
classified 
(RIFLE 
criteria). 
Until hospital 
discharge 
Omae et al. 
2014(40) 
Open partial 
nephrectomy. 
Retrospective 
study. 
Mannitol 20% 
100ml  15min 
before X-
Clamping 
No mannitol. n=55:  
(1:1.5) 
n.a. eGFR. 
Until 6th 
month. 
Power et al. 
2012(41) 
Minimal 
invasive 
partial 
nephrectomy. 
Retrospective 
study. 
12.5g 
mannitol i.v.  
No mannitol. n=285, 
(1.4:1) 
n.a. eGFR. 
Up to 13 
months. 
Cooper  et al 
2018 
Partial 
nephrectomy 
Retrospective 
study. 
Mannitol (12.5 
and 25g) 
No Mannitol n=476  
(1.5:1) 
n.a. eGFR at 6 
months 
Kong  et al. 
2018 
RALP 
Retrospective 
study. 
Mannitol  0.5 
g/kg 
No Mannitol n=468 (1:1) n.a. AKI 
according 
KDIGO, LOS 
Hospital, ICU 
admission 
rate, LOS 
ICU 
Up to 12 
months 
Table 2 
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ed
 
El
ig
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ili
ty
 
Id
en
tif
ic
at
io
n 
Records identified through 
database searching  (n =1,475) 
 
Additional records identified 
through other sources 
(n =  144) 
Records after duplicates removed 
(n = 1,538) 
Records screened 
(n = 1,538) 
Records excluded 
(n =1,505) 
Full-text articles assessed 
for eligibility 
(n = 33) 
Full-text articles excluded, 
with reasons 
(n = 13) 
n=3 full text not available in 
English or German 
n=1 conference Abstract 
n=3 full text n.a.  
n=1 used postoperatively  
n=3 no control group 
Studies included in 
qualitative synthesis 
(n = 22 ) 
Figure 1   
 
Figure 2 
 
 
Figure and table legends 
 
Figure 1:  PRISMA flowchart 
 
Figure 2:  Risk of bias about each risk of bias item and overall risk of bias 
presented as percentages across all included RCTs. 
 
Table 1: Characteristics of  prospective trials included  
β2M = β2-microglobulin, BUN = blood urea nitrogen, CABG = coronary 
artery bypass graft, CPB = cardiopulmonary bypass, DA = dopamine, 
ESWL = extracorporeal shock wave lithotripsy,  LOS = length of stay, 
uNAG = urinary N-acetylglucosaminidase, uNGAL = urinary neutrophil 
gelatinase-associated lipocalin, RALPN = robotic assisted laparoscopic 
partial nephrectomy, RIFLE = Risk/Injury/Failure/Loss/Endstage, sCR = 
serum creatinine, n.a. = not applicable, FEN = fractional excretion of 
sodium. 
0% 20% 40% 60% 80% 100%
Selection bias: Random sequence
generation
Selection bias:  Allocation concealment
Performance bias:  Blinding of
participants and personnel
Detection bias: Blinding of outcome
assessment
Attrition bias:  Incomplete outcome data
Reporting bias:  Selective reporting
Summary assessment: Risk of bias
% Low Risk of Bias % Unclear Risk of Bias % High Risk of Bias
 
Table 2:  Characteristics of retrospective studies included 
AKI = acute kidney injury, eGFR = estimated glomerular filtration rate, 
ICU = Intensive Care Unit, KDIGO = Kidney Disease Improving Global 
Outcomes; LOS = length of stay, RALP = robotic assisted laparoscopic 
prostatectomy, RIFLE = Risk/Injury/Failure/Loss/Endstage 
 
Table 3: Assessment of risk of bias for each RCT:  = low risk of bias;  = 
unclear risk of bias.;  = high risk of bias 
 
